雷尼替丁与复方丹参联合治疗急性胰腺炎35例疗效分析

目的：观察雷尼替丁与复方丹参联合治疗急性胰腺炎的疗效。方法：对确诊急性胰腺炎65例随机分成治疗组35例,对照组30例,分别用常规治疗,常规治疗加雷尼替丁与复方丹参静滴,连用4－7天,评价其疗效。结果：治疗组与对照组显效率分别为85.71%、43.3%,两组差异显著,P＜0.05。结论：两药联合应用不仅可减轻本病的炎症病变,且可改善心肌细胞营养状况。     

奥美拉唑三联疗法治疗小儿消化性溃疡的临床研究

目的探讨奥美拉唑三联疗法治疗小儿消化性溃疡的临床疗效。方法选择2020年1月—2021年1月在新郑市中医院就诊治疗的90例消化性溃疡患儿,按照入院先后顺序将所有患儿分为对照组和治疗组,每组各45例。对照组采用雷尼替丁三联疗法进行治疗:口服盐酸雷尼替丁胶囊,3～5 mg/(kg·d),2次/d;口服克拉霉素缓释片,15～20 mg/(kg·d),2次/d;口服阿莫西林胶囊,30～50mg/(kg·d),2次/d。治疗组采用奥美拉唑三联疗法进行治疗:口服奥美拉唑肠溶胶囊,0.6～0.8mg/(kg·d),1次/d;克拉霉素缓释片、阿莫西林胶囊用法用量均与对照组相同。两组患儿治疗6周。观察两组患儿的临床疗效,比较两组患儿治疗前后的炎性因子水平、胃肠道激素水平。结果治疗后,治疗组患儿的总有效率(93.33%)高于对照组(77.78%),组间比较有显著差异(P<0.05)。治疗后,两组患儿血清白细胞介素-25(IL-25)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)水平均明显降低,有统计学差异(P<0.05);治疗后治疗组患儿血清IL-25、CRP、TNF-α水平均低于对照...     

双黄连口服液与雷尼替丁用于口腔溃疡治疗的临床疗效观察

目的口腔溃疡以双黄连口服液及雷尼替丁治疗的效果。方法将84例口腔溃疡患者随机分为研究组与对照组,对照组雷尼替丁治疗,研究组联合双黄连口服液治疗,对比疗效。结果研究组疗效优于对照组(P<0.05)。结论口腔溃疡以双黄连口服液及雷尼替丁治疗效果理想。     

地洛他定联合雷尼替丁治疗慢性荨麻疹疗效观察

目的　探讨合并皮肤划痕症的慢性荨麻疹的最佳治疗方案。方法　慢性荨麻疹 80例随机分为两组 ,试验组用地洛他定联合雷尼替丁治疗 ,对照组单用地洛他定治疗 ,连续 4周。结果　试验组有效率为 90 .0 % ,对照组为82 .5 %。治疗 2 8天后两组总积分比较 ,试验组优于对照组 ,有显著性差异 (P <0 .0 0 1)。结论　地洛他定联合雷尼替丁治疗慢性荨麻疹疗效满意 ,安全性好。     

黄芪建中汤联合西药治疗消化性溃疡随机平行对照研究

[目的]观察黄芪建中汤联合西药治疗消化性溃疡疗效。[方法]使用随机平行对照方法,将200例门诊患者按随机数字表法分为两组。对照组100例雷尼替丁,150mg/次,2次/d。阿莫西林,1g/次,3次/d。吗叮啉,20mg/次,3次/d,餐前30min口服。治疗组100例黄芪建中汤(黄芪20g,炒白芍18g,桂枝、生姜各9g,炙甘草6g,大枣5枚,饴糖30g),1剂/d,水煎200mL,早晚口服。泛吐清水加干姜、吴茱萸、法半夏、茯苓;寒盛合附子理中汤;脾虚湿盛加陈皮、半夏;肾阳虚加巴戟天、仙茅;胃阴虚加石斛、沙参、玉竹;淤血合失笑散;肝气郁积合柴胡疏肝散;饮食停滞合保和丸;西药治疗同对照组。连续治疗28d为1疗程。观测临床症状、不良反应。治疗1疗程,判定疗效。[结果]治疗组痊愈60例,显效37例,有效2例,无效1例,总有效率99.00%。对照组痊愈47例,显效33例,有效11例,无效9例,总有效率89.00%。治疗组疗效优于对照组(P0.05)。[结论]黄芪建中汤联合西药治疗消化性溃疡效果显著,值得推广。     

依巴斯汀雷尼替丁联合治疗慢性荨麻疹疗效观察

目的观察依巴斯汀、雷尼替丁联合治疗慢性荨麻疹的疗效。方法62例患者随机分成两组,治疗组口服依巴斯汀与雷尼替丁,对照组口服西替利嗪与雷尼替丁,疗程4周,评估疗效,记录不良反应。结果治疗组和对照组有效率分别为84.26%和71.43%,差异无显著性(P>0.05)。结论依巴斯汀、雷尼替丁联合治疗慢性荨麻疹疗效好,安全可靠。     

Intolerance to Cereals Is Not Specific for Coeliac Disease

Background: While dyspeptic patients in primary care often receive empirical treatment with antisecretory drugs, a substantial number suffer from motility disturbances which may be associated with their complaints. We aimed to compare the effectiveness of treatment with antisecretory treatment with a prokinetic agent in uninvestigated dyspepsia. Methods: 563 patients presenting dyspeptic complaints to the general practitioner with a low likelihood of organic (ulcer, reflux or malignant) disease, i.e. absence of alarm symptoms or a history of peptic ulcer disease or gastro-oesophageal reflux disease were included. They entered a randomized, double-blind trial of 4 weeks of ranitidine 150 mg bid compared with 4 weeks of cisapride 10 mg bid, with 3 months follow-up. Treatment failure was defined as no response to treatment or a relapse of symptoms within the follow-up period. Also studied were the effect on dyspepsia severity, response to treatment after 4 weeks, and time to relapse. Results: For all randomized patients, the incidence of overall treatment success after 3 months follow-up with antisecretory treatment was 107/271 (39.5%) and with a prokinetic agent 122/282 (43.3%); the risk difference was 3.8% (95% CI-4.4% to 12.0%); the difference in symptom severity score after 4 weeks of treatment was 0.3; 95% CI-0.4% to 1.0%. For patients responding to 4 weeks of treatment, relapsefree time was 86 days in the prokinetic group and 79 days in the acid suppression group (P = 0.005). Conclusions: Antisecretory and prokinetic therapies are equally effective in primary care patients with uninvestigated dyspeptic complaints, though relapse rates are lower in patients treated with prokinetic treatment.     

Effect of long-term administration of ranitidine,a histamine H2 receptor antagonist,on bone metabolism in young growing rats

Background

Histamine regulates function of osteoclasts and osteoblasts, however data regarding the influence of histamine H2 receptors antagonists on bone tissue are ambiguous. Factors that influence growing skeleton may have an important impact on the peak bone mass and future risk of fractures. The aim of our study was the assessment of influence of ranitidine, on growing bones.

含雷贝拉唑与枸橼酸铋雷尼替丁的两种三联疗法治疗消化性溃疡的疗效比较

目的:比较含雷贝拉唑(RAZ)与枸橼酸铋雷尼替丁(RBC)的两种三联疗法治疗消化性溃疡的临床疗效。方法:将确诊为消化性溃疡的患者148例按随机数字表法均分为RAZ组和RBC组,分别给予RAZ/RBC+克拉霉素+甲硝唑的三联疗法治疗1周,之后两组患者均单服RAZ或RBC治疗3周,疗程共4周。治疗结束后比较两组患者的疗效、溃疡愈合率和幽门螺杆菌(Hp)根除情况,并观察治疗中的不良反应。结果:治疗结束后,RAZ组与RBC组患者的临床总有效率分别为88.7%、83.3%,Hp根除率分别为87.3%、93.1%,溃疡愈合率分别为85.9%、87.5%,两组比较差异均无统计学意义(P>0.05)。两组患者的不良反应均较轻,不影响治疗,可自行好转。结论:含RAZ与RBC的两种三联疗法治疗消化性溃疡的疗效相当,且安全性均较好。